Replimune Group (NASDAQ:REPL) Price Target Raised to $27.00

Replimune Group (NASDAQ:REPL) had its target price boosted by BMO Capital Markets from $18.00 to $27.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an outperform rating on the stock.

Other equities analysts have also issued research reports about the stock. HC Wainwright increased their target price on shares of Replimune Group from $17.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday. Jefferies Financial Group increased their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. Finally, JPMorgan Chase & Co. boosted their target price on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $19.14.

Replimune Group Stock Performance

Shares of NASDAQ REPL opened at $13.02 on Wednesday. Replimune Group has a 12-month low of $4.92 and a 12-month high of $17.00. The company has a market cap of $890.83 million, a PE ratio of -4.27 and a beta of 1.28. The stock has a 50 day simple moving average of $12.18 and a 200-day simple moving average of $11.28. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. On average, equities research analysts forecast that Replimune Group will post -2.91 EPS for the current year.

Insider Activity at Replimune Group

In other news, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the sale, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the transaction, the insider now owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Large investors have recently made changes to their positions in the company. Point72 DIFC Ltd acquired a new position in Replimune Group in the 2nd quarter worth approximately $57,000. Erste Asset Management GmbH purchased a new stake in shares of Replimune Group in the third quarter valued at $133,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Replimune Group by 82.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock worth $144,000 after buying an additional 5,926 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of Replimune Group by 81.7% during the third quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock valued at $165,000 after buying an additional 6,748 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new position in Replimune Group during the third quarter valued at $222,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.